The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
about
Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.Prognostic factors for long term survival in patients with advanced non-small cell lung cancer.Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.Bevacizumab-induced chronic interstitial pneumonia during maintenance therapy in non-small cell lung cancer.Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease.The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease.Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.The Safety and Efficacy of Treatment with Nab-Paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report.Lung cancer and interstitial lung disease: a literature review
P2860
Q35945391-5E8014AC-5EA3-4CB4-877B-80EC6C3AB932Q36924926-35D1A738-9076-4B60-8CF1-95739B1D1E9DQ39808352-A83F2230-86EE-4DF1-A41D-1AB08C5934A7Q39809681-C2C6A87C-AFF0-4671-8BE5-348528A671A6Q41541966-8F1029CA-2419-4463-B2F3-836E81DD6669Q47608285-D1BBDC5A-CB8B-462E-AD05-2F7A44490889Q48254839-39895AA2-64CA-433C-B693-55F8541E5EC1Q50046190-FBC0542A-29B2-4BFC-B335-8C783D5E4C49Q54729864-595FC4BF-9FA2-4CE6-82AE-E3E221FA66FCQ56243543-B1EA2F50-9B4A-4533-9576-955DE1991831
P2860
The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
The safety and efficacy of pac ...... ith interstitial lung disease.
@en
The safety and efficacy of pac ...... ith interstitial lung disease.
@nl
type
label
The safety and efficacy of pac ...... ith interstitial lung disease.
@en
The safety and efficacy of pac ...... ith interstitial lung disease.
@nl
prefLabel
The safety and efficacy of pac ...... ith interstitial lung disease.
@en
The safety and efficacy of pac ...... ith interstitial lung disease.
@nl
P2093
P2860
P1476
The safety and efficacy of pac ...... ith interstitial lung disease.
@en
P2093
Atsushi Nakagawa
Daichi Fujimoto
Kazuma Nagata
Keisuke Tomii
Koji Tamai
Kojiro Otsuka
Kyoko Otsuka
Nobuyuki Katakami
Ryoji Kato
Ryoko Shimizu
P2860
P2888
P304
P356
10.1007/S00280-014-2590-X
P577
2014-09-23T00:00:00Z